Publications of the Signal Transduction Laboratory


Since 2013

  1. Bauer, A. S., Nazarov, P. V., Giese, N. A., Beghelli, S., Heller, A., Greenhalf, W., Costello, E., Muller, A., Bier, M., Strobel, O., Hackert, T., Vallar, L., Scarpa, A., Büchler, M. W., Neoptolemos, J. P., Kreis, S., and Hoheisel, J. D. (2018) Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Int J Cancer 142: 1010-1021.
  2. Hövelmeyer, N., Hahn, M., Bürckert, J-P., Luttenberger, C., Klebow, S., Hess, M., Al-Maarri, M., Vogt, M., Reißig, S., Hallek, M., Buch, T., Wienecke-Baldacchino, A., Muller, C. P., Pallasch, C., Wunderlich, F. T., and Waisman, A. (2018) Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB. Leukemia 32: 72-82.
  3. Bongartz, H., Hessenkemper, W., Fensky, M., Fritsch, J., Mandel, K., Behrmann, I., Haan, C., Feller, S. M., and Schaper, F. (2017) Myeloproliferative neoplasm-associated Jak2-V617F induces Gab1 phosphorylation independent of pleckstrin homology domain-mediated plasma membrane recruitment. Cell Signal 35: 37-47.
  4. Rolvering, C., Zimmer, A. D., Kozar, I., Hermanns, H. M., Letellier, E., Vallar, L., Nazarov, P. V., Nicot, N., Ginolhac, A., Haan, S., Behrmann, I., and Haan, C. (2017) Crosstalk between different family members: IL27 recapitulates IFNg responses in HCC cells, but is inhibited by IL6-type cytokines. BBA Mol Cell Res 1864: 516-526.
  5. Mgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., Robert, C., Borg, C., Vielh, P., Chouaib, S., Berchem, G., and Janji, B. (2017) Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A 114: E9271-E9279.
  6. Cesi, G., Walbrecq, G., Zimmer, A., Kreis, S., and Haan, C. (2017) ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer 16: 102.
  7. Kozar, I., Cesi, G., Margue, C., Philippidou, D., and Kreis, S. (2017) Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochim Biophys Acta 1861: 2980-2992.
  8. Keller, A., Kreis, S., Leidinger, P., Maixner, F., Ludwig, N., Backes, C., Galata, V., Guerriero, G., Fehlmann, T., Franke, A., Meder, B., Zink, A., and Meese, E. (2017) miRNAs in ancient tissue specimens of the tyrolean iceman. Mol Biol Evol 34: 793-801.
  9. Hergovits, S., Mais, C., Haan, C., Costa-Pereira, A. P., and Hermanns, H. M. (2017) Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts. J Cell Mol Med 21: 3087-3099.
  10. Casper, M., Krawczyk, M., Behrmann, I., Glanemann, M., and Lammert, F. (2016) Variant PNPLA3 increases the HCC risk: prospective study in patients treated at the Saarland University Medical Center. Zeitschr Gastroenterol 54: 585-586.
  11. Zimmer, A. D., Walbrecq, G., Kozar, I., Behrmann, I., and Haan, C. (2016) Phosphorylation of the PDH complex precedes HIF-1-mediated effects and PDK1 upregulation during the first hours of hypoxic treatment in HCC cells. Hypoxia 4: 135-145.
  12. Battello, N., Zimmer, A. D., Goebel, C., Dong, X., Behrmann, I., Haan, C., Hiller, K., and Wegner, A. (2016) The role of HIF-1a in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer & Metabolism 4: 3.
  13. Heulot, M., Chevalier, N., Puyal, J., Margue, C., Michel, S., Kreis, S., Kulms, D., Barras, D., Nahimana, A., and Widmann, C. (2016) The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner. Oncotarget 7: 64342-64359.
  14. Cesi, G., Walbrecq, G., Margue, C., and Kreis, S. (2016) Transferring intercellular signals and traits between cancer cells: extracellular vesicles as "homing pigeons". Cell Commun Signal 14: 13. Review.
  15. Margue, C., Reinsbach, S., Philippidou, D., Beaume, N., Walters, C., Schneider, J. G., Nashan, D., Behrmann, I., and Kreis, S. (2015) Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget 6: 12110-12127.
  16. Haan, S., Bahlawane, C., Wang, J., Nazarov, P. V., Muller, A., Eulenfeld, R., Haan, C., Rolvering, C., Vallar, L., Satagopam, V. P., Sauter, T., and Wiesinger, M. Y. (2015) The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart. JAKSTAT 4: e1062596.
  17. Behrmann, I., Margue, C., and Kreis, S. (2015) Circulating microRNAs as candidate biomarkers for the surveillance of melanoma patients. EBioMedicine 2: 625-626.
  18. Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Loscuito, S., Heurtaux, T., Tardivel, A., Heuschling, P., and Dostert, C. (2015) NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS One 10: e0130624.
  19. Müller, S., Chen, Y., Ginter, T., Schäfer, C., Buchwald, M., Schmitz, L. M., Klitzsch, J., Schütz, A., Haitel, A., Schmid, K., Moriggl, R., Kenner, L., Friedrich, K., Haan, C., Petersen, I. Heinzel, T., and Krämer O.H. (2014) SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 5: 3184-9631.
  20. Margue, C.*, Philippidou, D.*, Reinsbach, S. E., Schmitt, M., Behrmann, I., and Kreis, S. (*contributed equally) (2013) New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. PLoS ONE 8: e73473.
  21. Wolf, A., Eulenfeld, R., Gäbler, K., Rolvering, C., Haan, S., Behrmann, I., Denecke, B., Haan, C.*, and Schaper, F.* (*contributed equally) (2013) Jak2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of Jak2-V617F-positive cells. JAK-STAT 2: 3e24574.
  22. Nazarov, P. V.*, Reinsbach*, S. E., Muller, A., Nicot, N., Philippidou, D., Vallar, L., and Kreis, S.  (* contributed equally) (2013) Interplay of microRNAs, transcription factors, and target genes: linking dynamic expression changes to function. Nucleic Acids Res 41: 2817-2831.
  23. Gäbler, K., Rolvering, C., Kaczor, J., Eulenfeld, R., Alvarez-Mendez, S., Berchem, G., Palissot, V., Behrmann, I., and Haan, C. (2013) Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. J Cell Mol Med 17: 265-276.
  24. Gäbler, K., Behrmann, I., and Haan, C. (2013) JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT 2: 3e25025.
  25. Schmitt, M. J., Margue, C., Behrmann, I., and Kreis, S. (2013) miRNA-29: A microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med 13: 572-585.
  26. Haan, C., and Haan, S. (2013) Co-immunoprecipitation protocol to investigate cytokine receptor associated proteins e.g. Janus kinases or other associated signaling proteins. Methods Mol Biol 967: 21-38.
  27. Haan. S., and Haan, C. (2013) Detection of activated STAT species using electrophoretic mobility shift assay (EMSA) and potential pitfalls arising from the use of detergents. Methods Mol Biol 967: 147-160.

From 2012 until 2003